TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16648775

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (20 Hz) over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 16
Study: 15565935

Group type: EXPERIMENTAL
Intervention: Budesonide (400microg) administered once daily via Turbuhaler
Number of subjects: 24

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (400microg) administered twice daily via metered-dose inhaler
Number of subjects: 24
Study: 11221554

Group type: EXPERIMENTAL
Intervention: Client-centered treatment (CCT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Client-centered treatment (CCT) with additional behavioral exposure treatment
Number of subjects: 68
Study: 9290860

Group type: EXPERIMENTAL
Intervention: Alcohol cues (valid and invalid); 2/3 of trials valid, 1/3 invalid; response target appeared after 100 or 500 milliseconds.
Number of subjects: 16
Study: 8512828

Group type: EXPERIMENTAL
Intervention: Epirubicin (30 mg m-2 weekly)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Doxorubicin (25 mg m-2 weekly)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 72
Study: 2880017

Group type: EXPERIMENTAL
Intervention: Antenatal doppler umbilical artery waveform studies
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no doppler studies)
Number of subjects: 300
Study: 30932950

Group type: EXPERIMENTAL
Intervention: Quetiapine-IR
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 42
Study: 30412478

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy plus GPR program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anti-TNF and conventional exercise therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 26475844

Group type: EXPERIMENTAL
Intervention: Ginger (1,000 mg daily for 10 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25107879

Group type: EXPERIMENTAL
Intervention: telcagepant 140 mg
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: telcagepant 280 mg
Number of subjects: 660

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 660
Study: 21795293

Group type: EXPERIMENTAL
Intervention: Didactic lectures followed by skills workshop and simulated case scenario (lecture‐first)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Simulated case scenario followed by didactic lectures (simulation‐first)
Number of subjects: 98
Study: 20485974

Group type: EXPERIMENTAL
Intervention: Experimental group A used fluor protector every three months under dentist's guidance.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Experimental group B used Casein phosphopeptide amorphous calcium phosphate (CPP-ACP) once a day.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group emphasized on daily oral hygiene.
Number of subjects: 75
Study: 17021598

Group type: EXPERIMENTAL
Intervention: Fermented soymilk (FS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-fermented soymilk (NFS)
Number of subjects: 16
Study: 16238982

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 490

Group type: COMPARATOR
Intervention: No cardiac resynchronization therapy (Control)
Number of subjects: 490
Study: 12074416

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.05% + fentanyl 0.00015%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.05% + fentanyl 0.00015%
Number of subjects: 40
Study: 10085055

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR at 10(8) CFU plus CVD 111 at 10(7) CFU
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR at 10(8) CFU plus CVD 111 at 10(6) CFU
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR alone at 10(8) CFU
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: CVD 111 alone at 10(7) CFU
Number of subjects: 170

Group type: COMPARATOR
Intervention: inactivated Escherichia coli placebo
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR either alone or in combination
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: CVD 111
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR and CVD 111 combination
Number of subjects: 170
Study: 7845291

Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 90% VO2max
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 120% VO2max
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intensive interval training sessions (10 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recovery period (6 days) after intensive interval training
Number of subjects: 12
Study: 2219460

Group type: EXPERIMENTAL
Intervention: Magnetic head Heaf gun
Number of subjects: 696

Group type: COMPARATOR
Intervention: Fixed head gun
Number of subjects: 696
Study: 342041

Group type: EXPERIMENTAL
Intervention: 1 g cephaloridine intraincisionally
Number of subjects: 209

Group type: COMPARATOR
Intervention: Irrigation with saline
Number of subjects: 209

Group type: COMPARATOR
Intervention: Povidone-iodine spraying
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Low risk operations
Number of subjects: 209
Study: 31119765

Group type: EXPERIMENTAL
Intervention: Arm 1: Four coaching sessions with an advanced practice nurse or social worker and four videoconference appointments during the oncologist-patient office visit.
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Arm 2: Four videoconference appointments with the oncologist and patient.
Number of subjects: 332

Group type: COMPARATOR
Intervention: Arm 3: Control group receiving access to information through a website.
Number of subjects: 332
Study: 27172269

Group type: EXPERIMENTAL
Intervention: Traditional‐based training group (TT; n = 11; 65‐75% of MAS, combined with 10‐12 repetition maximum [RM])
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Polarized training group (PT; n = 10; 35‐40% and 120% of MAS, combined with 5RM and 15RM)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (CG; n = 10)
Number of subjects: 31
Study: 26346433

Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture (WAA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 100
Study: 24257429

Group type: EXPERIMENTAL
Intervention: Tailored educational intervention
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Usual/normal care control
Number of subjects: 1072
Study: 21311759

Group type: EXPERIMENTAL
Intervention: Automatic activation of motor programs in the medial premotor cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contextual environmental settings
Number of subjects: 0
Study: 19647066

Group type: EXPERIMENTAL
Intervention: Monovalent HPV type 16 vaccine
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 17268408

Group type: EXPERIMENTAL
Intervention: Increased intake of vegetables (400 g/day) and fruit (300 g/day) through a group-based behavioral program for 3 months
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Increased intake of vegetables and fruit
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Increased intake of vegetables
Number of subjects: 138
Study: 15587230

Group type: EXPERIMENTAL
Intervention: Elated mood state (Velten procedure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depressed mood state (Velten procedure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral mood state (Velten procedure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low arousal state (induced through physical exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High arousal state (induced through physical exercise)
Number of subjects: 0
Study: 11573627

Group type: EXPERIMENTAL
Intervention: Alphadolone (25-500 mg, n = 9)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (lactose, n = 5)
Number of subjects: 14
Study: 9626375

Group type: EXPERIMENTAL
Intervention: Oral loading dose of carbamazepine 8 mg/kg in suspension form
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral loading dose of carbamazepine 8 mg/kg in tablet form
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both formulations (tablet and suspension)
Number of subjects: 6
Study: 7871774

Group type: EXPERIMENTAL
Intervention: Antiatherosclerotic diet with polyunsaturated fatty acids omega 3
Number of subjects: 112

Group type: COMPARATOR
Intervention: Antiatherosclerotic diet without omega 3
Number of subjects: 112
Study: 2899237

Group type: EXPERIMENTAL
Intervention: Halofantrine at 10 mg/kg for two doses
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Halofantrine at 8 mg/kg for three doses
Number of subjects: 106
Study: 30130144

Group type: EXPERIMENTAL
Intervention: 12-week Iyengar Yoga intervention given twice weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-weekly 12-week program of traditional exercise (e.g., walking, stationary cycling)
Number of subjects: 0
Study: 28587568

Group type: EXPERIMENTAL
Intervention: Collagenase treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Needle fasciotomy
Number of subjects: 39
Study: 25683775

Group type: EXPERIMENTAL
Intervention: Non-combustion inhaler type of tobacco product (NCIT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional cigarette (CC1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-smokers (NS)
Number of subjects: 80
Study: 23170990

Group type: EXPERIMENTAL
Intervention: Gemigliptin 50 mg
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 21600058

Group type: EXPERIMENTAL
Intervention: Exercise program and regular phone coaching to increase physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18641545

Group type: COMPARATOR
Intervention: 20 mg synthetic tetrahydrocannabinol (Marinol)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: five different types of Cannabis sativa extracts
Number of subjects: 18
Study: 16463153

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (MTX) infusion regimens (4-h vs 24-h infusion)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: MTX applied as 24-h infusion in all patients with lymphoblastic lymphoma and anaplastic large cell lymphoma
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: MTHFR 677 C-->T polymorphism
Number of subjects: 484
Study: 14620893

Group type: EXPERIMENTAL
Intervention: Cyst size of 2.4 mm (SE, 0.2 mm) for 13 to 21 weeks' gestation
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Cyst size of 1.9 mm (SE, 0.17 mm) for 22 to 38 weeks' gestation
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Texture analysis
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Interobserver and intraobserver kappa statistics
Number of subjects: 166
Study: 10897230

Group type: EXPERIMENTAL
Intervention: Consultation with physician
Number of subjects: 318

Group type: COMPARATOR
Intervention: Self-treatment (not consulting a physician)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Self-employed patients
Number of subjects: 318
Study: 8636549

Group type: EXPERIMENTAL
Intervention: Accelerated tissue-type plasminogen activator (t-PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation delay < 1 hour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation delay > 4 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment delay < 1 hour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment delay > 90 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time to treatment increase
Number of subjects: 0
Study: 1614041

Group type: EXPERIMENTAL
Intervention: High osmolar contrast
Number of subjects: 249

Group type: COMPARATOR
Intervention: Low osmolar contrast
Number of subjects: 249
Study: 6487076

Group type: EXPERIMENTAL
Intervention: Ban on sexual intercourse and communication of sexual preferences
Number of subjects: 16

Group type: COMPARATOR
Intervention: Communication of sexual preferences only
Number of subjects: 16
Study: 30773968

Group type: EXPERIMENTAL
Intervention: Eltrombopag as monotherapy (Arm A); starting dose 200 mg orally daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Continuation of HMA (Arm B)
Number of subjects: 29
Study: 28914713

Group type: EXPERIMENTAL
Intervention: Hyperfibrinolytic (HF) phenotype
Number of subjects: 680

Group type: COMPARATOR
Intervention: Shutdown (SD) phenotype
Number of subjects: 680

Group type: COMPARATOR
Intervention: Physiologic (PHYS) phenotype
Number of subjects: 680
Study: 26490015

Group type: EXPERIMENTAL
Intervention: Physician education and audit/feedback on antibiotic prescribing quantity and quality
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control practices (no intervention)
Number of subjects: 88
Study: 24606090

Group type: EXPERIMENTAL
Intervention: 50 mg PVI once daily
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 100 mg PVI once daily
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 200 mg PVI once daily
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 100 mg PVI twice daily
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 200 mg PVI twice daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: 50 mg PIO via im injection once daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: 100 mg PIO via im injection once daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: 200 mg PIO via im injection once daily
Number of subjects: 58
Study: 22313739

Group type: EXPERIMENTAL
Intervention: Ginger (1.5 g/d in 3 divided doses every 8 hours) plus standard antiemetic regimen (granisetron plus dexamethasone)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard antiemetic regimen (granisetron plus dexamethasone)
Number of subjects: 100
Study: 20809807

Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% (Durezol) 4x/day (n=50)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Prednisolone acetate 1% (Pred Forte) 8x/day (n=40)
Number of subjects: 90
Study: 17684881

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus intravenous hydrocortisone (200 mg first, then 100 mg TID for 48 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy (complete bed rest, hydration, acetaminophen and pethidine)
Number of subjects: 60
Study: 16124967

Group type: EXPERIMENTAL
Intervention: Technique 2 (leg into extension while maintaining internal rotation after insertion of the femoral component)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Technique 1 (thigh flexed and internally rotated throughout implantation of the femoral component)
Number of subjects: 19
Study: 17876971

Group type: EXPERIMENTAL
Intervention: High-frequency exercise (n = 8)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High-frequency exercise + group-based intervention (n = 8)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low-frequency exercise (control) (n = 7)
Number of subjects: 23
Study: 10666547

Group type: EXPERIMENTAL
Intervention: Intramuscular capsaicin 100 microg/1 ml
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular capsaicin 100 microg/20 microl
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intradermal capsaicin 100 microg/20 microl
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular capsaicin 1 ml
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular capsaicin 20 microl
Number of subjects: 12
Study: 9463118

Group type: EXPERIMENTAL
Intervention: Pattern and flash visual evoked potentials (VEP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no ocular and neuroophthalmologic diseases)
Number of subjects: 72
Study: 1730811

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate injections (3 mg/kg.week, im)
Number of subjects: 13
Study: 6381461

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30374945

Group type: EXPERIMENTAL
Intervention: Nike Vaporfly (NVF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nike Vaporfly (NVF) matched in weight to ADI shoe (NVF+)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nike Zoom Matumbo 3 (NZM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Adidas Adizero Adios 3 (ADI)
Number of subjects: 24
Study: 29771789

Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg once daily (QD)
Number of subjects: 797

Group type: COMPARATOR
Intervention: Raltegravir 400 mg twice daily (BID)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 797
Study: 27899103

Group type: EXPERIMENTAL
Intervention: TTE illustration (time-to-event format)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Emoticons (ten-year risk illustration)
Number of subjects: 304
Study: 25239225

Group type: EXPERIMENTAL
Intervention: Trabectedin 1.3 mg/m(2) once every 3 weeks (1/3 treatment arm)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Trabectedin 0.58 mg/m(2) every week for 3 of 4 weeks (3/4 treatment arm)
Number of subjects: 52
Study: 23107042

Group type: EXPERIMENTAL
Intervention: Metformin (3 g daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 20146700

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 0
Study: 18408707

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) x 60 min
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 35% carbamide peroxide (CP) x 30 min
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) x 30 min with halogen activation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) x 30 min with diode laser activation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) x 30 min with plasma arc curing light
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control groups (matched)
Number of subjects: 100
Study: 15838067

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention designed to achieve and maintain a 7% weight loss and 150 minutes of exercise per week
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Metformin, 850 mg twice daily
Number of subjects: 1711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 1711
Study: 12456458

Group type: EXPERIMENTAL
Intervention: FIO(2) = 1.0 (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VC maneuver + FIO(2) = 1.0 (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VC maneuver + FIO(2) = 0.4 (n = 10)
Number of subjects: 30
Study: 10713806

Group type: EXPERIMENTAL
Intervention: Once daily gentamicin (4 mg/kg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Twice daily gentamicin (2.5 mg/kg)
Number of subjects: 73
Study: 7568637

Group type: EXPERIMENTAL
Intervention: Imagery during negatively valent conditions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Imagery during high-arousal conditions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Imagery during high-arousal imagery
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Imagery during low-arousal imagery
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Zygomatic and corrugator activity
Number of subjects: 48
Study: 29438649

Group type: EXPERIMENTAL
Intervention: Cannabidiol as an anticonvulsant drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cannabidiol
Number of subjects: 0
Study: 27561153

Group type: EXPERIMENTAL
Intervention: Telepsychiatry-based culturally sensitive collaborative treatment (T-CSCT)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 190
Study: 24910991

Group type: EXPERIMENTAL
Intervention: Broccoli sprout homogenates (BSH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (alfalfa sprout homogenate)
Number of subjects: 100
Study: 23227679

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture therapy (4 weeks, 3-5 treatments per week)
Number of subjects: 73
Study: 19560639

Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 172

Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 172
Study: 17233779

Group type: EXPERIMENTAL
Intervention: Sildenafil 1 hour before a meal and placebo 30-60 minutes before planned coitus
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo 1 hour before a meal and sildenafil 30-60 minutes before coitus
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sildenafil during a meal and placebo 30-60 minutes before coitus
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo during a meal and sildenafil 30-60 minutes before coitus
Number of subjects: 48
Study: 15124981

Group type: EXPERIMENTAL
Intervention: R-roscovitine (50, 100, 200, 400, or 800 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: R-roscovitine (50, 100, 200, 400, or 800 mg) after breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carboxylate metabolite
Number of subjects: 12
Study: 11773168

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin-based) followed by radical surgery (type III to V radical hysterectomy plus systematic pelvic lymphadenectomy)
Number of subjects: 441

Group type: COMPARATOR
Intervention: External-beam radiotherapy (45 to 50 Gy) followed by brachyradiotherapy (20 to 30 Gy)
Number of subjects: 441
Study: 9839764

Group type: COMPARATOR
Intervention: Theophylline alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Theophylline in combination with donepezil (5 mg, once daily for 10 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 12
Study: 7807427

Group type: EXPERIMENTAL
Intervention: Sedation
Number of subjects: 62

Group type: COMPARATOR
Intervention: No Sedation
Number of subjects: 62
Study: 2510270

Group type: EXPERIMENTAL
Intervention: Rioprostil, 600 micrograms
Number of subjects: 182

Group type: COMPARATOR
Intervention: Ranitidine, 300 mg
Number of subjects: 182
Study: 998148

Group type: EXPERIMENTAL
Intervention: Atropine (0.1 mg/10 kg intravenously 2 min before induction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halothane‐N2O/O2 anesthesia without atropine (control group)
Number of subjects: 0
Study: 31272251

Group type: EXPERIMENTAL
Intervention: RTXM83
Number of subjects: 272

Group type: COMPARATOR
Intervention: R-rituximab
Number of subjects: 272